National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Nusinersen (Spinraza®) is indicated for the treatment of 5q spinal muscular atrophy (SMA)

NCPE Assessment Process
Ongoing
Rapid review received 11/07/2017
Rapid review completed 02/08/2017
Rapid Review outcome Full pharmacoeconomic evaluation recommended
Full pharmacoeconomic evaluation commissioned by HSE 14/08/2017
Pre-submission consultation with Applicant 12/09/2017
Submission received from applicant 31/10/2017
Preliminary review sent to applicant 28/11/2017
NCPE assessment re-commenced 06/12/2017
Applicant factual accuracy check 08/12/2017
NCPE assessment re-commenced 14/12/2017
NCPE assessment completed 19/12/2017
Full pharmacoeconomic assessment outcome Reimbursement not recommended at the submitted price

Summary